Expert Interview
Evaluation of Amgen’s Repatha® (Evolocumab) Phase 3 VESALIUS-CV Trial for Reduction in Risk For Adverse Cardiovascular Events
Ticker(s): AMGNInstitution: University of Michigan
- Interventional Cardiologist and Clinical Scientist at the University of Michigan
- Manages 100 patients per month for inheritied heart diseases
- Research focuses on exploring the molecular and cellular response to myocardial stress and its role in cardiac remodeling
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
